Radek Špíšek
Sotio Biotech, Prague, Czech Republic
www.sotio.com
 


Radek Špíšek graduated from the 1st Faculty of Medicine of Charles University in Prague and received his Ph.D. in immunology. Between 2000 and 2002, he worked at Institute de Biologie of Université de Nantes in France. He spent three years (2005-2007) on the team led by Professor Ralph Steinman, a medicine and physiology Nobel laureate, at the Laboratory of Cellular Physiology and Immunology / Center for Immunology and Immune Diseases, Rockefeller University, New York. In his scientific efforts, he focuses on tumor immunology and tumor immunotherapy. He is a Professor at Charles University’s 2nd Faculty of Medicine. He has received postgraduate clinical certification in pediatrics and in allergology and clinical immunology. Radek Špíšek joined SOTIO in 2010 where he has been a member of the company’s management and has overseen research and manufacturing. He was appointed CEO in March 2018.

Selected publications:

An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. Fucikova J, Hensler M, Kasikova L, Lanickova T, Pasulka J, Rakova J, Drozenova J, Fredriksen T, Hraska M, Hrnciarova T, Sochorova K, Rozkova D, Sojka L, Dundr P, Laco J, Brtnicky T, Praznovec I, Halaska MJ, Rob L, Ryska A, Coosemans A, Vergote I, Cibula D, Bartunkova J, Galon J, Galluzzi L, Spisek R. Clin Cancer Res. 2022

  • Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, Stenzl A, Csöszi T, Filipovic Z, Goncalves F, Prokhorov A, Cheung E, Hussain A, Sousa N, Bahl A, Hussain S, Fricke H, Kadlecova P, Scheiner T, Korolkiewicz RP, Bartunkova J, Spisek R; VIABLE Investigators. JAMA Oncol. 2022
  • TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Fucikova J, Rakova J, Hensler M, Kasikova L, Belicova L, Hladikova K, Truxova I, Skapa P, Laco J, Pecen L, Praznovec I, Halaska MJ, Brtnicky T, Kodet R, Fialova A, Pineau J, Gey A, Tartour E, Ryska A, Galluzzi L, Spisek R. Clin Cancer Res. 2019.
  • Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, Vosahlikova S, Klouckova J, Church SE, Cremer I, Kepp O, Kroemer G, Galluzzi L, Salek C, Spisek R. Blood. 2016
  • Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, Spísek R. Cancer Res. 2011 Jul 15